Healthcare Cost Crisis

The U.S. bears a significant burden in global healthcare costs, paying nearly half of the world's pharmaceutical revenues despite being only 3% of the population. This dynamic raises questions about the fairness of drug pricing, especially considering taxpayer funding for basic science. The discussion emphasizes that while many claim the current system is unsustainable, it remains operational until a critical breaking point is reached. What will it take to shift this trajectory of escalating healthcare expenditures?